Lin Christine, Shi Julianne, Moore Amanda, Khetani Salman R
School of Biomedical Engineering (C.L., S.R.K.) and Department of Mechanical Engineering (S.R.K.), Colorado State University, Fort Collins, Colorado; Department of Bioengineering (C.L., S.R.K.), University of Illinois at Chicago, Chicago, Illinois; Hepregen Corporation, Medford, Massachusetts (J.S., A.M.).
School of Biomedical Engineering (C.L., S.R.K.) and Department of Mechanical Engineering (S.R.K.), Colorado State University, Fort Collins, Colorado; Department of Bioengineering (C.L., S.R.K.), University of Illinois at Chicago, Chicago, Illinois; Hepregen Corporation, Medford, Massachusetts (J.S., A.M.)
Drug Metab Dispos. 2016 Jan;44(1):127-36. doi: 10.1124/dmd.115.066027. Epub 2015 Oct 9.
Accurate prediction of in vivo hepatic drug clearance using in vitro assays is important to properly estimate clinical dosing regimens. Clearance of low-turnover compounds is especially difficult to predict using short-lived suspensions of unpooled primary human hepatocytes (PHHs) and functionally declining PHH monolayers. Micropatterned cocultures (MPCCs) of PHHs and 3T3-J2 fibroblasts have been shown previously to display major liver functions for several weeks in vitro. In this study, we first characterized long-term activities of major cytochrome P450 enzymes in MPCCs created from unpooled cryopreserved PHH donors. MPCCs were then used to predict the clearance of 26 drugs that exhibit a wide range of turnover rates in vivo (0.05-19.5 ml/min per kilogram). MPCCs predicted 73, 92, and 96% of drug clearance values for all tested drugs within 2-fold, 3-fold, and 4-fold of in vivo values, respectively. There was good correlation (R(2) = 0.94, slope = 1.05) of predictions between the two PHH donors. On the other hand, suspension hepatocytes and conventional monolayers created from the same donor had significantly reduced predictive capacity (i.e., 30-50% clearance values within 4-fold of in vivo), and were not able to metabolize several drugs. Finally, we modulated drug clearance in MPCCs by inducing or inhibiting P450s. Rifampin-mediated CYP3A4 induction increased midazolam clearance by 73%, while CYP3A4 inhibition with ritonavir decreased midazolam clearance by 79%. Similarly, quinidine-mediated CYP2D6 inhibition reduced clearance of dextromethorphan and desipramine by 71 and 22%, respectively. In conclusion, MPCCs created using cryopreserved unpooled PHHs can be used for drug clearance predictions and to model drug-drug interactions.
利用体外试验准确预测体内肝脏药物清除率对于合理估算临床给药方案至关重要。使用未汇集的原代人肝细胞(PHH)的短期悬浮液和功能逐渐衰退的PHH单层细胞来预测低周转率化合物的清除率尤其困难。先前已表明,PHH与3T3-J2成纤维细胞的微图案共培养物(MPCC)在体外数周内可呈现主要肝功能。在本研究中,我们首先对由未汇集的冷冻保存的PHH供体制备的MPCC中主要细胞色素P450酶的长期活性进行了表征。然后,MPCC被用于预测26种在体内具有广泛周转率(0.05 - 19.5毫升/分钟·千克)的药物的清除率。MPCC分别在体内值的2倍、3倍和4倍范围内预测了所有测试药物73%、92%和96%的药物清除率值。两个PHH供体之间的预测具有良好的相关性(R² = 0.94,斜率 = 1.05)。另一方面,由同一供体制备的悬浮肝细胞和传统单层细胞的预测能力显著降低(即体内值4倍范围内的清除率值为30 - 50%),并且无法代谢几种药物。最后,我们通过诱导或抑制细胞色素P450来调节MPCC中的药物清除率。利福平介导的CYP3A4诱导使咪达唑仑清除率增加73%,而用利托那韦抑制CYP3A4使咪达唑仑清除率降低79%。同样,奎尼丁介导的CYP2D6抑制分别使右美沙芬和地昔帕明的清除率降低71%和22%。总之,使用冷冻保存的未汇集的PHH制备的MPCC可用于药物清除率预测并模拟药物 - 药物相互作用。